Business Description
Emmaus Life Sciences Inc
NAICS : 325414
SIC : 2836
ISIN : US62857N2027
Description
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | -1.97 | |||||
| Debt-to-Equity | -0.62 | |||||
| Debt-to-EBITDA | 11.68 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -14.67 | |||||
| Beneish M-Score | -3.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.5 | |||||
| 3-Year EBITDA Growth Rate | -22.1 | |||||
| 3-Year EPS without NRI Growth Rate | 1.1 | |||||
| 3-Year FCF Growth Rate | 16.6 | |||||
| 3-Year Book Growth Rate | -94.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.17 | |||||
| 9-Day RSI | 49.53 | |||||
| 14-Day RSI | 49.7 | |||||
| 6-1 Month Momentum % | -58.74 | |||||
| 12-1 Month Momentum % | -69.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.14 | |||||
| Quick Ratio | 0.12 | |||||
| Cash Ratio | 0.02 | |||||
| Days Inventory | 547.74 | |||||
| Days Sales Outstanding | 81.09 | |||||
| Days Payable | 2086.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.1 | |||||
| Shareholder Yield % | 134.91 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.7 | |||||
| Operating Margin % | 0.09 | |||||
| Net Margin % | -17.11 | |||||
| FCF Margin % | -7.86 | |||||
| ROA % | -10.56 | |||||
| ROIC % | 0.03 | |||||
| ROC (Joel Greenblatt) % | 129.64 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.1 | |||||
| EV-to-EBIT | 12.01 | |||||
| EV-to-EBITDA | 11.91 | |||||
| EV-to-Revenue | 1.65 | |||||
| EV-to-FCF | -21.01 | |||||
| Price-to-Median-PS-Value | 0.03 | |||||
| Earnings Yield (Greenblatt) % | 8.33 | |||||
| FCF Yield % | -84.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:EMMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Emmaus Life Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.428 | ||
| EPS (TTM) ($) | -0.09 | ||
| Beta | 16.34 | ||
| Volatility % | 9852.29 | ||
| 14-Day RSI | 49.7 | ||
| 14-Day ATR ($) | 0.004324 | ||
| 20-Day SMA ($) | 0.03118 | ||
| 12-1 Month Momentum % | -69.6 | ||
| 52-Week Range ($) | 0.0001 - 0.13215 | ||
| Shares Outstanding (Mil) | 63.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Emmaus Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Emmaus Life Sciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Emmaus Life Sciences Inc Frequently Asked Questions
What is Emmaus Life Sciences Inc(EMMA)'s stock price today?
The current price of EMMA is $0.03. The 52 week high of EMMA is $0.13 and 52 week low is $0.00.
When is next earnings date of Emmaus Life Sciences Inc(EMMA)?
The next earnings date of Emmaus Life Sciences Inc(EMMA) is 2025-02-19 Est..
Does Emmaus Life Sciences Inc(EMMA) pay dividends? If so, how much?
Emmaus Life Sciences Inc(EMMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers